Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Kadmon

Status and phase

Completed

Phase 1

Conditions

Cancer

Treatments

Drug: XL647

Study type

Interventional

Funder types

Industry

Identifiers

NCT00336765

XL647-002

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to adults with advanced solid tumors.

Enrollment

31 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has histologically confirmed malignancy that is metastatic or unresectable
Subject has disease that is assessable by tumor marker, physical, or radiologic means
Subject is at least 18 years old
Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
Subject has a life expectancy ≥ 3 months
Subject has normal organ and marrow function
Subject gives written informed consent
Subject must use an accepted method of contraception during the study
Female subjects of childbearing potential must have a negative pregnancy test

Exclusion criteria

Subject has received anticancer treatment within 30 days of first dose of XL647
Subject has received another investigational agent within 30 days of first dose of XL647
Subject has known brain metastases
Subject has corrected QT interval (QTc) of > 0.45 seconds
Subject is currently receiving anticoagulation therapy with warfarin
Subject has uncontrolled intercurrent illness
Subject is pregnant or breastfeeding
Subject has known HIV